Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

里克·皮尔斯将与来自勃林格殷格翰、RA Capital和ILiAD Biotechnologies的演讲嘉宾共同参加关于早期临床开发的讨论

CAMBRIDGE, Mass.

马萨诸塞州剑桥

,

，

June 8, 2026

2026年6月8日

/PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq:

/美通社/ -- Decoy Therapeutics, Inc.（纳斯达克：

DCOY

DCOY

), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London..

），一家开创可设计多重抗病毒药物（D-MAVs™）这一全新类别的生物技术公司，该类药物旨在靶向跨病毒家族保守的共同病毒机制，今日宣布其首席执行官里克·皮尔斯（Rick Pierce）将于2026年6月11日在伦敦金丝雀码头出席由hVIVO plc（AIM: HVO）主办的资本市场日活动并发表演讲。

The half-day event brings together analysts, institutional investors and media to examine how specialist partners support faster, better-informed decisions in early drug development, including the strategic value of human challenge trials in moving novel therapeutics toward the clinic.

这场为期半天的活动汇聚了分析师、机构投资者和媒体，共同探讨专业合作伙伴如何支持更快速、更明智的早期药物研发决策，包括人体挑战试验在推动新型疗法走向临床过程中的战略价值。

Decoy is advancing a pipeline of D-MAVs built on its AI-enabled IMP³ACT platform, designed to shorten the path from concept to clinic. Led by a pan-coronavirus program, the pipeline is targeting the clinic in 2027.

Decoy 正在推进基于其人工智能赋能的 IMP³ACT 平台构建的 D-MAV 产品管线，旨在缩短从概念到临床的路径。该管线由一个泛冠状病毒项目主导，目标是在 2027 年进入临床试验阶段。

'The companies that reach patients fastest are usually the ones that choose the right development partners early,' said Pierce. 'Human challenge models are one of the tools that can shorten that path, and that aligns closely with how we are building Decoy. I'm looking forward to a candid discussion about what it takes to develop a new class of antivirals at speed.'.

“能够最快触达患者的公司，通常是那些在早期就选择了合适开发伙伴的公司。”皮尔斯表示，“人体挑战模型是缩短这一路径的工具之一，这与我们构建Decoy的理念高度契合。我期待就如何快速开发新一代抗病毒药物进行坦诚的讨论。”

Attendance is limited; analysts, investors and media can register interest at

出席人数有限；分析师、投资者和媒体可以登记意向，网址为

[email protected]

[email protected]

, and a recording will be posted to hVIVO's website after the event.

，活动结束后，录像将发布在 hVIVO 的网站上。

About Decoy Therapeutics

关于 Decoy Therapeutics

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP³ACT platform, which combines AI-assisted design and rapid synthesis, Decoy develops peptide antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment.

Decoy Therapeutics 是一家生物技术公司，率先开创“可设计多重抗病毒药物”（D-MAVs）这一全新类别。这类抗病毒药物经工程化设计，靶向病毒共有的机制，使单一且可适应的药物能够对多种病毒发挥作用。Decoy 依托专有的 IMP³ACT 平台，该平台融合人工智能辅助设计与快速合成技术，致力于开发肽类抗病毒药物，以加速其进入临床试验，并拓展病毒预防与治疗的可能性边界。

The company's lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease..

该公司的领先候选药物靶向多种呼吸道病毒，旨在减轻病毒性疾病对健康和社会造成的负担。

Forward Looking Statements

前瞻性陈述

This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management.

本新闻稿包含经《1995年私人证券诉讼改革法案》界定的有关Decoy的“前瞻性陈述”，包括对其核心资产预期里程碑的实现以及Decoy的未来前景。这些陈述可能涉及未来计划、趋势、事件、经营业绩或财务状况等方面的目标、意图和预期，基于Decoy管理层当前的信念以及管理层所作的假设和目前可获得的信息。

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'can,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions.

前瞻性陈述通常包括具有预测性质的陈述，这些陈述依赖于或提及未来事件或条件，并包含诸如“可能”、“将”、“能够”、“应该”、“会”、“预期”、“预计”、“计划”、“很可能”、“相信”、“估计”、“规划”、“打算”等词语以及其他类似表述。

Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any .

非历史事实的陈述均为前瞻性陈述。前瞻性陈述基于当前的信念和假设，这些信念和假设受风险和不确定性的影响，并不保证未来的表现。由于各种因素，实际结果可能与任何前瞻性陈述中包含的结果存在重大差异，包括但不限于：公司无法获得足够资金以执行其业务计划的风险，以及与Decoy的产品和开发计划相关的风险，包括任何未预见的问题。

IND

印度

application process and the potential of the IMP

申请流程及IMP的潜力

3

3

ACT

ACT

™

商标

platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC.

平台。我们敦促读者仔细审阅并考虑公司在向美国证券交易委员会（SEC）提交的报告中所作出的各项披露，包括其截至2025年12月31日财政年度的Form 10-K年度报告，以及经其Form 10-Q季度报告和其他向SEC提交的文件修订或补充的内容。

If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected..

如果这些风险或不确定性中的一项或多项成为现实，或者基本假设被证明不正确，Decoy 的实际结果可能与预期或预测的结果存在重大差异。

SOURCE Decoy Therapeutics, Inc

来源：Decoy Therapeutics, Inc

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示